Dallas, TX, March 11, 2021 – Puration, Inc. (OTC Pink: PURA) and PAOG Group, Inc. (OTC Pink: PAOG) today confirmed the two companies continue to work together on developing a variety of cannabis centric applications through a partnership that initiated when PAOG acquired PURA’s cannabis cultivation business last year.
The PURA and PAOG partnership include a pending distribution of PAOG stock to PURA shareholders. PURA shareholders are intended to receive one share of PAOG for every PURA share they hold. The intended distribution has been submitted for review by FINRA. Once the review process is complete, PURA and PAOG plan to promptly proceed with the intended distribution.
Operationally, PURA and PAOG are working together on PURA’s Farmersville Brands project. PURA with PAOG’s help, is building a 70-acre facility designed to provide interactive, demonstrable education on the potential of hemp to provide environmentally sustainable alternatives to over $1 trillion in existing industrial products and services currently damaging the environment.
The 70-acre facility is the cornerstone of PURA’s overall Farmersville Hemp Brand strategy designed to accelerate the overall market growth of hemp derived products beyond the industry forecasted 2027 $15 billion market size.
PAOG is specifically partnering with PURA in Farmersville on the construction and operation of indoor, pharmaceutical grade, hemp growing facilities, and the construction and operation of a cannabis extraction lab.
PURA and PAOG are joined on the Farmersville project by North American Cannabis Holdings, Inc. (OTC Pink: USMJ) and Alkame Holdings, Inc. (OTC Pink: ALKM) in PURA’s Farmersville Hemp Brand strategy.
For more information on Puration, visit http://www.purationinc.com
Disclaimer/Safe Harbor: This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company’s current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that Alkame will achieve significant sales, the failure to meet schedule or performance requirements of the Company’s contracts, the Company’s liquidity position, the Company’s ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.